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Background: The International Depression/anxiety Epidemiological Study (TIDES) in the UK aimed: (i) to establish the prevalence of anxiety and
depression amongst people with CF compared to a normative sample; (ii) to establish the association between mood, demographic and clinical
variables; and (iii) to provide guidance for specialist-referral decision-making.
Methods: Patients (≥12 years) completed the Hospital Anxiety and Depression Scale (HADS). CF-HADS scores, expressed as percentiles, were
compared with a normative sample. Multiple-regression analysis explored associations between demographic, clinical and mood variables.
Results: Thirty-nine CF centres recruited 2065 patients. Adults with CF were similar in terms of anxiety and depression to the general population.
Adolescents with CF were less anxious and depressed. For adult patients, older age, unemployment for health reasons and poor lung function were
associated with disordered mood. Gender-speciﬁc CF-percentile scores were calculated.
Conclusion: Surveillance, with attention to gender and risk factors is advocated. This work provides unique benchmark scores to aid referral
decision-making.
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Advances in the diagnosis and treatment of cystic fibrosis (CF)
have led to dramatic improvements in prognosis [1,2]; however,
arduous treatment regimens [3], considerable morbidity and early
mortality [1] impact on psychological health which remains a
critical target for assessment and intervention.
There is a complex relationship between psychological health
and physical health [4]. Those with respiratory disease have an
increased risk for co-morbid anxiety and depression [5–7], with
routine assessment recommended [8]. However, the findings in
CF are inconsistent, as there are difficulties interpreting and
comparing results across studies because of different sampling
approaches, measurement instruments and a lack of consensus on
clinical cut-off scores. Single-centre reports of adult patients cite
depression rates of 17–30%, linking depression with worse
adherence, poorer lung-function and quality of life (QoL) [9–11].
Lower and elevated rates of depression have been reported in
children, adolescents and young adults who have CF compared
with healthy controls [12,13]. Normal [12–14] and elevated
levels of anxiety [15,16] have been reported in adult and adoles-
cent patients.
To address the limitations of previous studies The Interna-
tional Depression/anxiety Epidemiology Study (TIDES) aimed
to conduct rigorous evaluation of depression and anxiety in CF
patients and parent–caregivers in eight European countries and
the US. Although some preliminary TIDES findings have been
presented in abstract form, to date only one national patient
data-set has been published (TIDES-Germany). In this study,
patients were no more or less depressed than the general
population; however, adults with CF had greater elevated
symptoms of anxiety than healthy controls. Younger patients
reported fewer symptoms of both depression and anxiety than
older ones [17].
This paper presents TIDES-UK patient data, which aimed:
(i) to estimate prevalence of depression and anxiety amongst
adolescents and adults with CF in the UK in comparison to
a normative, adult UK sample; (ii) to estimate associations
between mood, demographic and clinical variables; and (iii)
to provide guidance for specialist referral decision-making.
Rates of depression and anxiety were expected to be higher
in those with CF than in the general population and elevated
symptoms were expected to be associated with worse health
status.2. Materials and methods
2.1. Study design
A cross-sectional study involving paediatric and adult UK CF
centres was undertaken. National Research Ethics Service
approval was granted (NRES 07/Q1205) with site-specific
approval being obtained from local Research and Development
units. All participants provided written consent. Parental consent
and child assent were given for those under 16 years. Final
consent was taken in April 2012.2.2. Subjects and procedure
All patients (≥12 years) except for transplant-recipients
were asked to participate in the study during routine out-patient
appointments between October 2009 and April 2012. Demo-
graphic, clinical, and mood variables were collected and the
Hospital Anxiety and Depression Scale (HADS) [18] was
completed immediately prior to consultations. The HADS was
scored within a week with referral pathways in place (referral to
CF psychosocial professional or liaison with external mental
health services).
2.3. Measures
2.3.1. Demographic and clinical variables
Demographic and clinical data were obtained from partic-
ipants and verified by medical records where appropriate.
Not all clinics collected every variable but when possible, the
following data were obtained: age, gender, height, weight,
FEV1% predicted, education-level, employment status, diabe-
tes, current IV-antibiotics, nutritional supplements, enteral tube
feeds, intravenous access device and whether the person was
diagnosed with diabetes, haemoptysis or pneumothorax in the
past six months. Whether the participant was listed for
transplant, had a current prescription for anti-depressants or
anxiolytics or was engaged in counselling for depression or
anxiety, was documented.
2.3.2. Hospital Anxiety and Depression Scale (HADS)
The HADS was identified as the most appropriate TIDES
measure because of its extensive reliability and validity data [19],
good sensitivity and specificity [20] and international transla-
tions. It is a 14-item (7 depression, 7 anxiety), self-report scale
that evaluates and quantifies anxiety and depression in hospital
settings without somatic items. Respondents consider how they
have been feeling over the past 7 days and answer on 4-point
Likert scaling (scored ‘0’–‘3’), yielding a total anxiety or
depression score of between 0 and 21. Depression and anxiety
are categorised according to published thresholds [21] (‘none’:
raw scores b7; ‘mild’: 8–10; ‘moderate’: 11–15; ‘severe’:≥16);
however, there is little agreement about the clinical value of these
which makes it difficult to interpret data and establish referral
pathways for specialist assessment [22].
An alternative approach of using a HADS centile-structure
was proposed in a large study of non-clinical UK adults (978
women, 810 men) in community settings. This sample was
deemed representative of the UK population in terms of age,
gender and occupational status [23]. Using these normative data,
gender-specific tables converted raw HADS scores to percentiles
which establish the comparative scarcity of a person's depression
or anxiety score and augment management decisions based on
comparative severity.
2.4. Statistical analysis
To provide contextual information about the estimated
prevalence of depression and anxiety in CF, the categorised
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or ‘severe’) was compared between the UK normative adult
sample and the adult CF sample, and between the latter and the
adolescent CF sample, using chi-squared or Fisher's exact tests
(there are noUK normative data for adolescents) and independent
samples t-tests. Graphical comparisons were made between
samples by comparing the percentile plots of the empirical
cumulative distribution functions.
Regression analysis was used to explore the influence of
demographic and clinical variables on depression and anxiety.
Preliminary regressions using the total depression and anxiety
scores showed highly skewed residuals and heterogeneity in the
residual variance. Therefore, these scores were transformed
firstly to the percentile of the empirical cumulative distribution of
the observed score and secondly, using the logistic transforma-
tion. The empirical cumulative distribution function used was the
one appropriate to the gender and the set of data, CF adult or CF
adolescent. These transformations achieved homogeneity of
variance and satisfactory approximation to the normal distribution,
thus, supporting valid P-values with which to assess significant
associations.
The following strategy was used to identify variables asso-
ciated with depression and anxiety. Variables were divided into
two groups for both adults and adolescents; the core group of
variables which were available for most individuals and the
secondary group of variables, which were available for a reduced
subset of individuals (not all variables were collected in every
clinic). Regressions were undertaken that included both core and
secondary variables using the reduced sample size of individuals
who had all variables available. These regressions tested the
associations between depression and anxiety with the secondary
variables. Regressions were then repeated using only core
variables, but utilising the larger sample size. These regressions
tested the associations between depression and anxiety with the
core variables.
3. Results
3.1. Study population
The 39 study sites (25 adult, 14 paediatric) included 23/48 CF
centres registered with the UK CF Trust and 16 regional clinics.
The smallest site had 8 patients; the largest, 530. Twenty-three
sites (59%) recruited N70% of their clinic population, with a
further 6 (15%) recruiting N60%. A total of 1780 adults and 285
adolescents with CF were included in the study (total n = 2065).
This represented 45.2% of the total UK adult CF population and
18.3% of adolescents (12–17 years), based on UK CF Trust
Registry data [1], having similar age and FEV1 distributions and
median BMI. Demographic and clinical characteristics are shown
in Table 1.
Direct or indirect access to a clinical psychologist was
available in 28 of the 39 (72%) participating sites. Of the 23
participating major centres, integrated clinical psychology posts
were established in 18 (78%) with indirect access via a generic
hospital clinical psychologist being available in a further 3 (13%).
In the 16 participating regional clinics whilst there was no directaccess, support was available indirectly in 7 (44%), via network
centres or community services.
Internal reliability of the HADS was robust with satisfac-
tory Cronbach's alpha coefficients for depression (0.82 and
0.72) and anxiety (0.80 and 0.85) for adults and adolescents,
respectively.
3.2. Estimated prevalence of depression and anxiety
Table 2 shows the estimated prevalence of depression and
anxiety in men and women with CF, adolescent boys and girls
with CF and UK normative data together with mean scores.
In terms of prevalence, men with CF were significantly more
depressed (Χ2 = 10.4; P = 0.014) and anxious (Χ2 = 24.3;
P b 0.001) than men from the general population, but the
differences were small. However, although mean depression
score was lower (3.4 for men with CF; 3.6 for UK men) and was
not significantly different (P = 0.200), mean anxiety score was
the same for both groups at 5.7. Adolescent boys with CF were
less depressed (Χ2 = 19.0; P b 0.001) and anxious (Χ2 = 12.5;
P = 0.006) than adult CF men. Mean depression and anxiety
scores for adolescent boys with CF were significantly lower than
that for men with CF (depression 1.9 P b 0.001; anxiety 4.3
P b 0.001).
Women with CF were not significantly different to adult
women from the general population for both depression (Χ2 =
2.38; P = 0.50) and anxiety (Χ2 = 1.03; P = 0.79). In fact mean
depression score was significantly lower for CF women at 3.4
compared to 4.0 for UK adult women (P b 0.001) and mean
anxiety score was also lower but not significantly so (6.6 versus
6.8, P = 0.311). Adolescent girls with CF were not significantly
different to women with CF for both depression (Χ2 = 5.10;
P = 0.15) and anxiety (Χ2 = 5.53; P = 0.14) but this is likely
the result of a small sample size for adolescents, since the
P-values are close to 15%. Mean depression score was
significantly lower at 2.4 for girls with CF compared to 3.4
for women with CF (P b 0.001). Mean anxiety score was
significantly lower at 5.7 for girls with CF compared to 6.6 for
women with CF (P = 0.011).
In summary, adults with CFwere similar in terms of depression
and anxiety to the general population, with any differences being
small. However, adolescent boys and girls with CF were less
depressed and anxious than their adult counterparts. This is
demonstrated graphically in Figs. 1 and 2.
3.3. Associations between mood, demographic and
clinical variables
3.3.1. Adults with CF
The core variables comprised: BMI, FEV1% predicted, age,
education, employment status, routine/unwell visit and current
use of intravenous antibiotics. Secondary variables were: diabetic
condition, development of diabetes and haemoptysis in previous
6 months, listed for transplant, nutritional supplements, enteral
tube feeding and a port-a-cath in situ. Pneumothorax was ex-
cluded because only 4 individuals had experienced this in the past
6 months.
Table 1
Demographic and clinical characteristics of the CF participants in the HADS study.
Adults (18 years and older) Adolescents (12 to 17 years)
Sample size Men
929
Women
851
All
1780
Boys
136
Girls
149
All
285
Age
12–17 136 (100) 149 (100) 285 (100)
18–23 326 (35.1) 315 (37.1) 641 (36.0)
24–29 268 (28.8) 243 (28.6) 511 (28.7)
30–39 209 (22.5) 177 (20.8) 386 (21.7)
40–49 99 (10.7) 79 (9.3) 178 (10.0)
50–59 17 (1.8) 23 (2.7) 40 (2.2)
60+ 10 (1.1) 13 (1.5) 23 (1.3)
BMI (kg m−2)
Mean (SD) 22.8 (3.7) 21.9 (3.7) 22.4 (3.7) 19.9 (3.5) 20.2 (3.1) 20.1 (3.3)
Range 12.5–42.8 12.7–39.7 12.5–42.8 13.4–36.3 13.6–33.2 13.4–36.3
FEV1% predicted
Mean (SD) 61.6 (24.8) 60.1 (23.4) 60.9 (24.1) 80.0 (18.7) 73.6 (21.3) 76.6 (20.3)
Range 12–135 15.132 12–135 29–129 18–122 18–129
Education
No formal qualns 97 (10.6) 68 (8.1) 165 (9.4)
O levels/GCSE 267 (29.1) 257 (30.5) 524 (29.7)
A levels/equivalent 236 (25.7) 240 (28.4) 476 (27.0)
University degree 184 (20.0) 137 (16.2) 321 (18.2)
Postgrad. studies 40 (4.4) 48 (5.7) 88 (5.0)
Professional qualns 95 (10.3) 94 (11.1) 189 (10.7)
Employment
Working full-time 378 (41.1) 237 (28.3) 615 (35.0)
Working part-time 158 (17.2) 205 (24.5) 363 (20.7)
Not working — health 211 (23.0) 209 (25.0) 420 (23.9)
Not working — other 172 (18.7) 186 (22.2) 358 (20.4)
Type of visit
Routine 856 (92.6) 773 (91.7) 1629 (92.2) 133 (97.8) 141 (95.2) 274 (96.5)
Unwell 68 (7.4) 70 (8.3) 138 (7.8) 3 (2.2) 7 (4.7) 10 (3.5)
Diabetic
No 225 (75.8) 186 (69.4) 411 (72.7) 78 (91.8) 69 (85.2) 147 (88.6)
Yes 72 (24.2) 82 (30.6) 154 (27.3) 7 (8.2) 12 (14.8) 19 (11.4)
Diabetic in last 6 m
No 885 (95.9) 804 (94.9) 1689 (95.4) 131 (98.5) 140 (96.6) 271 (97.5)
Yes 38 (4.1) 43 (5.1) 81 (4.6) 2 (1.5) 5 (3.4) 7 (2.5)
Haemoptysis in last 6 m
No 225 (75.8) 196 (73.1) 421 (74.5) 84 (98.8) 75 (92.6) 159 (95.8)
Yes 72 (24.2) 72 (26.9) 144 (25.5) 1 (1.2) 6 (7.4) 7 (4.2)
On IV antibiotics
No 883 (95.6) 772 (91.7) 1655 (93.7) 126 (94.7) 133 (91.7) 259 (93.2)
Yes 41 (4.4) 70 (8.3) 111 (6.3) 7 (5.3) 12 (8.3) 19 (6.8)
Listed for transplant
No 903 (97.7) 821 (97.5) 1724 (97.6) 133 (100.0) 144 (99.3) 277 (99.6)
Yes 21 (2.3) 21 (2.5) 42 (2.4) 0 (0.0) 1 (0.7) 1 (0.4)
Nutritional suppl.
No 166 (55.9) 172 (64.2) 338 (59.8) 53 (62.4) 57 (70.4) 110 (66.3)
Yes 131 (44.1) 96 (35.8) 227 (40.2) 32 (37.6) 24 (29.6) 56 (33.7)
Enteral tube feeds
No 277 (93.3) 253 (94.4) 530 (93.8) 76 (89.4) 67 (82.7) 143 (86.1)
Yes 20 (6.7) 15 (5.6) 35 (6.2) 9 (10.6) 14 (17.3) 23 (13.9)
Port-a-cath in situ
No 239 (80.7) 178 (66.4) 417 (73.9) 61 (71.8) 38 (46.9) 99 (59.6)
Port-a-cath in situ
Yes 57 (19.3) 90 (33.6) 147 (26.1) 24 (28.2) 43 (53.1) 67 (40.4)
Taking antidepressant
No 864 (93.5) 745 (88.6) 1609 (91.2) 133 (100.0) 141 (97.9) 274 (98.9)
Yes 60 (6.5) 96 (11.4) 156 (8.8) 0 (0.0) 3 (2.1) 3 (1.1)
Counselling for mood
No 862 (93.3) 771 (91.7) 1633 (92.5) 130 (97.7) 133 (92.4) 263 (94.9)
Yes 62 (6.7) 70 (8.3) 132 (7.5) 3 (2.3) 11 (7.6) 14 (5.1)
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ary variables (292 men, 261 women), the percentage variance
accounted for (R2) was 21% for men and 27.5% for women. For
men, no secondary variable showed any association with level of
depression. For women, only recent haemoptysis was associated
with increased depression. In the regressions with only core
variables (885 men, 811 women), R2 was 15.5% for men and
15.9% for women; again a poor level of explanation. Generally,
for men and women, increasing age, not working due to health
reasons, decreasing FEV1% predicted and a clinic visit whilst
unwell were associated with increased depression scores. BMI,
level of educational attainment and current IVs showed no
association with depression.
3.3.1.2. Anxiety. In the regressions with core and secondary
variables (292 men, 261 women), R2 was 8.7% for men and
16.6% for women. For men, no secondary variable was associated
with level of anxiety. For women, only recent haemoptysis
predicted higher levels of anxiety. In the regressions with only
core variables (885 men, 811 women) R2 was 4.4% for men and
7.0% for women; a poor level of explanation. For both men and
women, age group and employment status were both significant.
Generally, increasing age predicted increased anxiety scores.
Typically, those in full-time employment reported the least
anxiety, whereas those not working due to health reasons reported
the highest levels. For women, an ‘unwell’ visit was associated
with heightened anxiety and the use of IVs was related to lower
anxiety. FEV1% predicted, BMI and level of educational
attainment showed no association with anxiety.
For the demographic and clinical variables that demonstrated a
statistically significant association with depression or anxiety,
Table 3 shows unadjusted mean values of depression and anxiety
together with the P-values from the regressions. The means are
for the individuals who were included in the appropriate
regression which generated the P-value. Unadjusted means are
given because adjusted values would be difficult to interpret
following the data transformations. Although some variables
were shown to be statistically significant, the means in Table 3
indicate that they were not always clinically relevant.
3.3.2. Adolescents with CF
Core variables included: BMI, FEV1% predicted, routine/
unwell visit and current intravenous antibiotics. Secondary
variables comprised: diabetes, nutritional supplements, enteral
tube feeding and a port-a-cath in situ. Other variables were
excluded because too few individuals were involved. In the
regression analyses of core and secondary variables, 71 boys and
77 girls were included; R2 was 4.6% for boys and 24.3% for girls
for depression and 8.4% for boys and 11.8% for girls for anxiety.
For both boys and girls, no secondary variable showed any
association with anxiety. For boys, none of the secondary variables
showed any association with depression, but for girls, a port-a-cath
in situ was associated with elevated levels of depression and
diabetes with reduced depression. Table 3 also includes unadjusted
means and P-values for diabetes and port-a-cath in situ for
depression in girls. In regressions with core variables, 114 boys
and 139 girls were included and R2 was 3.1% of boys and 4.6%of girls for depression and 1.6% of boys and 4.4% of girls for
anxiety; a negligible level of explanation. For both boys and girls,
no core variable showed any association with anxiety.
3.4. Specialist referral threshold scores
Table 4 shows the depression and anxiety scores for referral
based on the top 20%, 10%, 5% and 1% of patients with CF. If
referral decisions are based on raw HADS scores (e.g., a score of
11 for ‘moderate’ anxiety) then men would be referred if they
were in the top 10% of the anxiety distribution for men with CF.
Women would be referred in the top 20% of the anxiety
distribution for CF women. For boys with CF, referral would be
only in the top 5% and for girls in the top 10%. Therefore,
clinicians may want to refer patients for depression and anxiety
based on the same top percentile for all groups. If referral for
anxiety was based on a score placing a patient in the top 5% of the
anxiety distribution, then men with CF would be referred at score
13, women at score 14, boys at 10 and girls at 12. For depression
the analogous scores are 10, 10, 6 and 8 respectively.
4. Discussion
TIDES-UK is the first study to investigate rates of depression
and anxiety in a large, multi-centred, UK sample of people
with CF. Adults with CF had a similar estimated prevalence
of depression and anxiety as the general population. This was
contrary to expectations [24] and cannot be explained by the
decade time-difference between the normative and CF samples, as
more recent normative data established virtually identical means
and standard deviations [25]. Moreover, the estimated prevalence
of depression reported by TIDES-Germany was also similar to
that of a normative sample [17], albeit that estimated UK
anxiety was higher than that reported in Germany, which in
turn was higher than the respective normative group. Comparison
with single-centre studies or narrative reviews which report
variable rates of depression and anxiety is not particularly useful
given the methodological limitations and varying results of such
reports.
Adolescents with CF were less depressed and anxious than
their adult counterparts, with elevated depression scores being
minimal in adolescent boys. Adherence problems in this group are
frequently noted and together with a decline in lung-function
between the ages of 12 and 16 years [1], there remains a clinically
compelling case for maintaining close observation.
The importance of evaluating and attending to, patients' and
relatives' emotional well-being is gaining worldwide support.
In the UK psychological provision is well-established as
part of CF management, with centres mandated to provide
integrated clinical psychological care as part of the service
specification [26]. It is plausible that low rates of depression
and anxiety were detected in this study as a result of there being
direct or indirect access to a clinical psychologist in 91% of
participating major centres and 44% of regional clinics (72%
access overall).
Surveillance with special attention to gender and the risk
factors FEV1% predicted, age and work status, is advocated
Table 2
Percentages of samples in each diagnosis group for HADS anxiety and
depression score, means and standard deviations (SD).
Men Women
Normative
adults
CF
adults
CF
boys
Normative
adults
CF
adults
CF
girls
Sample size 810 929 119 978 850 144
Anxiety score
None (0–7) % 73.0 69.9 84.9 61.0 61.5 70.1
Mild (8–10) % 18.0 18.6 10.1 23.0 21.3 14.6
Moderate
(11–15) %
8.0 9.5 5.0 13.0 14.0 13.9
Severe (16–21) % 1.0 2.0 0.0 3.0 3.2 1.4
P-value b0.001 0.006 0.794 0.137
Mean 5.7 5.7 4.3 6.8 6.6 5.7
SD 3.7 3.9 3.2 4.1 4.3 3.8
P-value 1.00 b0.001 0.311 0.011
Depression score
None (0–7) % 91.0 86.9 99.2 86.0 88.1 94.4
Mild (8–10) % 6.0 10.0 0.8 9.0 7.3 2.8
Moderate
(11–15) %
2.3 2.8 0.0 4.0 3.9 2.8
Severe (16–21) % 0.7 0.3 0.0 1.0 0.7 0.0
P-value 0.014 b0.001 0.498 0.146
Mean 3.6 3.4 1.9 4.0 3.4 2.4
SD 3.2 3.3 2.0 3.6 3.4 2.9
P-value 0.200 b0.001 b0.001 b0.001
Based on Zigmond and Snaith [21] recommended cut-off scores (mild: raw
scores between 8 and 10; moderate: 11–15; severe: 16 and above). Normative
UK adults from Crawford et al. [23].
Fig. 1. Percentile plots for anxiety scores for (a) adult men with CF (solid line) and n
women (broken line), (c) adult men with CF (solid line) and boys with CF (broken
Normative UK adult data from [23].
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of men and 4.6% of women and ‘moderate/severe’ anxiety was
reported by 11.5% of CF men and 17.2% of CF women. Poor
lung-function was associated with elevated depression scores
in adults, a finding reported by several studies [8,9,17]. The
combination of depression and poor lung-function had a
greater adverse effect on QoL than poor lung-function alone
[10]. Older-age and not working due to health reasons were
also associated with higher rates of depressive and anxiety
symptoms. These results highlight important psychosocial
benefits of living with CF and being in full-time employment
[27,28] and a timely reminder that the new era of CF care with
mutation-specific treatments, affords greater confidence in
psychologically preparing adolescents for the full opportuni-
ties of adult life. Additionally, for adult females, psychopa-
thology was associated with haemoptysis and attending clinic
when unwell (although lower levels of depression were reported
whilst on intravenous [IV] treatment). In adolescent girls, having
a port-a-cath in situ was associated with higher depression scores
and consistent with poor QoL reporting [29].
The HADS is a practical tool for estimating depression and
anxiety. It is reliable and valid and remains popular in clinical
settings due to its ease of use and the weaknesses of other
measures. Whether or not the HADS is the most appropriate
assessment tool in CF remains to be evaluated. It does not
represent the multi-dimensional nature of depression and omits
somatic items which can be linked to depression or anxiety but
does have advantages over other scales (e.g., the CES-Dormative men (broken line), (b) adult women with CF (solid line) and normative
line) and (d) adult women with CF (solid line) and girls with CF (broken line).
Fig. 2. Percentile plots for depression scores for (a) adult men with CF (solid line) and normative men (broken line), (b) adult women with CF (solid line) and
normative women (broken line), (c) adult men with CF (solid line) and boys with CF (broken line) and (d) adult women with CF (solid line) and girls with CF (broken
line). Normative UK adult data from [23].
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PHQ-9 includes an item on suicidal ideation requiring resource-
intensive administration, which is considered in the TIDES-UK
pilot data [30]). However, such considerations are tempered by
questions over the validity of utilising case-finding or screening
questionnaires alone. Systematic review of 16 studies with 7576
patients, suggests that the adoption of screening strategies using
standardised questionnaires without organisational enhancements
are not justified [31].
TIDES-UK data present a unique opportunity to establish
meaningful management of HADS thresholds and clinical
responses via the conversion of raw scores into gender-specific,
CF-centile scores, which determine who should be kept under a
watchful eye, undergo further assessment and be referred for
psychosocial and/or mental health intervention (Table 4). Previ-
ously this has been a contentious issue. In the original paper [18]
of the 18 patients in the ‘borderline’ range for depression (8+)
only 3 presented as definite cases. Of the 20 patients in the same
category for anxiety (again 8+), only 1 presented as a definite
case. It is wrong to consider these as diagnostic of clinical
depression and/or anxiety. Instead it is vital that elevated scores
are followed by clinical assessment and diagnosis, with referral
for psychological intervention when necessary. In accordance
with clinical psychology opinion for hospitalised patients, a
cut-off at the 90th percentile on the HADS depression scale was
deemed the appropriate point for referral for clinical interview
with a psychologist [32]. Similarly, in a community sample
evaluating the longitudinal effect of anxiety and depression on
blood pressure, the 90th percentile of the HADS were alsoestimated to be the appropriate clinical cut-off points [33]. We
advocate ‘watchful waiting’ at the 80th centile, ‘follow-up with
clinical discussion in theCF team’ at the 90th centile, ‘referral to
mental health for diagnostic assessment and intervention’ at the
95th centile and ‘emergency referral’ at the 99th centile.
Whilst TIDES-UK was a large study in a comparatively
rare disease, with excellent clinical representation of the UK
CF population, some sampling bias may still have occurred.
There was a lower response rate for adolescents and this
should temper the interpretation of these data. Refusal rates
were unavailable and out-patient clinic recruitment possibly
excluded poor/non-attendees. The reasons for refusal/poor
attendance remain unknown but may have been influenced
by psychological symptoms, leading to an under-estimate of
psychopathology. The study was cross-sectional but provides
robust prevalence estimates, risk factors and critically, threshold
referral information. We await longitudinal follow-up to evaluate
the trajectory and predictors of depression and anxiety over
time.
5. Conclusions
Adults with CF in the UK have similar rates of depression and
anxiety to the general population. Adolescent patients were less
anxious and depressed than their adult counterparts. Older age, not
working due to health and poor lung-function were associated with
disordered mood. With no consensus on thresholds for specialist
assessment or onward referral, converted gender-specific CF
percentiles provide unique benchmark profiles that aid clinical
Table 3
Unadjusted mean values and standard errors (SE) of significant predictors of anxiety and depression scores for adults and adolescents with cystic fibrosis together
with P-values from regression analyses.
Anxiety Depression
Men P-value Women P-value Men P-value Women P-value
Sample size 885 811 885 811
Age
18–23 5.0 (0.2) 6.1 (0.3) 2.7 (0.2) 2.9 (0.2)
24–29 5.7 (0.2) 0.041 6.9 (0.3) 0.048 3.1 (0.2) 0.078 3.4 (0.2) 0.007
30–39 6.1 (0.3) 0.004 6.6 (0.3) 0.390 3.7 (0.2) b0.001 3.5 (0.3) 0.151
40–49 6.5 (0.4) 0.004 6.9 (0.5) 0.504 4.7 (0.4) b0.001 3.3 (0.1) 0.198
50+ 5.5 (0.9) 0.909 6.5 (0.2) 0.061 4.4 (0.8) 0.066 4.7 (0.6) 0.005
Employment
Full-time 5.2 (0.2) 5.6 (0.3) 2.5 (0.1) 2.3 (0.2)
Part-time 6.0 (0.3) 0.010 6.5 (0.3) 0.016 3.2 (0.2) 0.008 2.8 (0.2) 0.104
Not working — health 6.6 (0.3) b0.001 8.0 (0.3) b0.001 5.1 (0.3) b0.001 5.2 (0.3) b0.001
Not working — other 5.2 (0.3) 0.278 6.3 (0.3) 0.024 3.0 (0.3) 0.002 3.1 (0.2) 0.006
On IV antibiotics
No 6.6 (0.2)
Yes 6.3 (0.5) 0.024
Type of visit
Routine 6.5 (0.2) 3.2 (0.1) 3.2 (0.1)
Unwell 7.9 (0.6) 0.010 4.7 (0.4) 0.035 5.0 (0.5) b0.001
FEV1% predicted
Normal (N100%) 2.3 (0.4) 2.4 (0.4)
Mild (70–100%) 2.7 (0.2) 0.399 2.5 (0.2) 0.612
Moderate (40–69%) 3.3 (0.2) 0.283 3.6 (0.2) 0.038
Severe (b40%) 4.5 (0.2) 0.019 4.1 (0.3) 0.036
Sample size 261 261
Hemoptysis in last 6 m
No 6.3 (0.3) 2.8 (0.2)
Yes 8.8 (0.6) 0.001 5.5 (0.5) b0.001
Girls P-value
Sample size 77
Diabetes
No 2.8 (0.4)
Yes 1.8 (0.8) 0.027
Port-a-cath in situ
No 1.5 (0.3)
Yes 3.6 (0.6) 0.010
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further assess or refer on.
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